On October 16, 2026, a Phase 3 clinical trial for survodutide was registered on ClinicalTrials.gov. The trial, titled "ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease," carries the identifier NCT07850063.
The trial's current status is listed as not yet recruiting. It is designated a Phase 3 study, indicating a later-stage investigation in the drug development process.
As described in its title, the trial aims to examine survodutide in participants with overweight or obesity who also have fatty liver disease, with a focus on heart structure and function. No results, recruitment timelines, or additional trial details beyond this registration have been reported.
Survodutide remains classified as an unapproved compound under research investigation. This trial update reflects only the registration of the study and its current status as of the date listed. No outcome data, efficacy findings, or safety conclusions are available at this stage, since the study has not yet begun enrolling participants.
Readers interested in learning more about survodutide's background and research history can refer to the compound overview for additional context.